These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17332314)

  • 21. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine.
    Orlandi F; Venanzi FM; Concetti A; Yamauchi H; Tiwari S; Norton L; Wolchok JD; Houghton AN; Gregor PD
    Clin Cancer Res; 2007 Oct; 13(20):6195-203. PubMed ID: 17947487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.
    Provinciali M; Papalini F; Orlando F; Pierpaoli S; Donnini A; Morazzoni P; Riva A; Smorlesi A
    Cancer Res; 2007 Mar; 67(5):2022-9. PubMed ID: 17332330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous neu DNA vaccine can be as effective as xenogenic neu DNA vaccine by altering administration route.
    Tu CF; Lin CC; Chen MC; Ko TM; Lin CM; Wang YC; Lai MD
    Vaccine; 2007 Jan; 25(4):719-28. PubMed ID: 16962215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9.
    Aurisicchio L; Peruzzi D; Conforti A; Dharmapuri S; Biondo A; Giampaoli S; Fridman A; Bagchi A; Winkelmann CT; Gibson R; Kandimalla ER; Agrawal S; Ciliberto G; La Monica N
    Clin Cancer Res; 2009 Mar; 15(5):1575-84. PubMed ID: 19240169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs.
    Peruzzi D; Mesiti G; Ciliberto G; La Monica N; Aurisicchio L
    Vaccine; 2010 Feb; 28(5):1201-8. PubMed ID: 19944791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
    Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
    Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
    Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
    Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting.
    Seavey MM; Paterson Y
    Breast Cancer (Dove Med Press); 2009; 1():19-30. PubMed ID: 24367160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice.
    Renard V; Sonderbye L; Ebbehøj K; Rasmussen PB; Gregorius K; Gottschalk T; Mouritsen S; Gautam A; Leach DR
    J Immunol; 2003 Aug; 171(3):1588-95. PubMed ID: 12874253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines.
    Singh R; Paterson Y
    Cancer Immunol Immunother; 2007 Jun; 56(6):927-38. PubMed ID: 17131121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain.
    Rolla S; Marchini C; Malinarich S; Quaglino E; Lanzardo S; Montani M; Iezzi M; Angeletti M; Ramadori G; Forni G; Cavallo F; Amici A
    Hum Gene Ther; 2008 Mar; 19(3):229-40. PubMed ID: 18269312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Listeria monocytogenes activated dendritic cell based vaccine for prevention of experimental tumor in mice.
    Khamisabadi M; Arab S; Motamedi M; Khansari N; Moazzeni SM; Gheflati Z; Hadjati J
    Iran J Immunol; 2008 Mar; 5(1):36-44. PubMed ID: 18319523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perspectives on the development of a therapeutic HER-2 cancer vaccine.
    Renard V; Leach DR
    Vaccine; 2007 Sep; 25 Suppl 2():B17-23. PubMed ID: 17630057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
    Bai T; Luoh SW
    Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model.
    Yoon SH; Lee JM; Cho HI; Kim EK; Kim HS; Park MY; Kim TG
    Cancer Gene Ther; 2009 Jun; 16(6):489-97. PubMed ID: 19096447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MMP11: a novel target antigen for cancer immunotherapy.
    Peruzzi D; Mori F; Conforti A; Lazzaro D; De Rinaldis E; Ciliberto G; La Monica N; Aurisicchio L
    Clin Cancer Res; 2009 Jun; 15(12):4104-13. PubMed ID: 19509157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
    Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
    J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety profiles of genetic vaccines against human Her-2/neu in cynomolgus monkeys.
    Ko HJ; Kim YJ; Kim YS; Kim JM; Ho SH; Jeong JG; Oh SM; Chae JA; Kim CY; Lee PS; Kang CY
    Gene Ther; 2008 Oct; 15(20):1351-60. PubMed ID: 18480847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.